Version 2.1.0.0

Abstract

Abstract: DESCRIPTION (provided by applicant): The overall goal of this project is to develop a rapid, highly sensitive assay to detect the presence of anthrax. To achieve this goal we have developed a novel, proprietary technology with several advantages over currently used PCR-based methods. This technology, called SPIATM [single primer isothermal amplification] can amplify nucleic acids in an isothermal, homogeneous manner with expected sensitivity and specificity equal to and perhaps greater than PCR. Furthermore, the method does NOT suffer from the cross-contamination problems of PCR. In this Phase I proposal we expect to validate these claims and develop a test suitable for widespread use. Therefore we will a) optimize SPIATM and demonstrate sensitivity and specificity of SPIATM control sequences, b) demonstrate use of SPIATM using B. anthracis sequences, and c) validate SPIATM using B. subtills spores. In Phase II we will integrate this technology into detection device(s) with expanded field studies to evaluate sensitivity, specificity, etc.

Thesaurus Terms:
Bacillus anthracis, DNA primer, anthrax, bioassay, nucleic acid sequence, technology /technique development
communicable disease diagnosis, monitoring device
biotechnology, bioterrorism /chemical warfare

Institution:	NUGEN TECHNOLOGIES, INC.
	821 INDUSTRIAL RD, UNIT A
	SAN CARLOS, CA 94070
Fiscal Year:	2002
Department:
Project Start:	01-JUL-2002
Project End:	31-DEC-2002
ICD:	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
IRG:	ZRG1